Hospital
Beth Israel Medical Center
Beth Israel Medical Center was paid $9.23M by Medicaid between Jan 2018 and Dec 2024, across 140 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoBETH ISRAEL MEDICAL CENTER
BROOKLYN, NY 11234
BROOKLYN, NY 11234
33aNPI1174768071assigned 12/05/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.23M
24GClaims233,307
24DCodes billed140
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#85 of 231
Median peer was paid$561K
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 807 | $18K | |
| 2019 | 13,542 | $445K | |
| 2020 | 35,676 | $1.40M | |
| 2021 | 54,504 | $2.09M | |
| 2022 | 53,075 | $2.09M | |
| 2023 | 45,707 | $1.87M | |
| 2024incomplete | 29,996 | $1.31M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 12,770 | 12,211 | $1.98M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 10,367 | 9,831 | $1.57M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 9,762 | 9,333 | $1.54M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 6,016 | 5,582 | $983K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 2,076 | 2,047 | $372K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 3.5% | 6,218 | 5,975 | $321K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 2,146 | 2,104 | $317K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.2% | 14,712 | 13,737 | $207K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 1,797 | 1,661 | $194K |
| 86850 | 1.5% | 4,078 | 3,760 | $141K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 1,480 | 1,446 | $132K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 709 | 683 | $111K |
128 more codes
| 93975 | 1.0% | 349 | $94K | |
| 87428 | <1% | 3,572 | $86K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 265 | $82K |
| 86901 | <1% | 4,191 | $74K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,475 | $66K |
| 86900 | <1% | 4,203 | $64K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 393 | $64K |
| 80053 | Comprehensive metabolic panel | <1% | 3,876 | $55K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 345 | $53K |
| 80076 | <1% | 6,675 | $49K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,140 | $44K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,015 | $44K |
| 36000 | <1% | 2,486 | $42K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,173 | $41K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,291 | $40K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,153 | $39K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,871 | $30K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,349 | $28K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 133 | $27K |
| 93976 | <1% | 85 | $26K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 138 | $25K |
| 83880 | <1% | 1,388 | $24K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,092 | $20K |
| 87631 | <1% | 510 | $18K | |
| 0002A | <1% | 643 | $18K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 559 | $15K |
| 0001A | <1% | 695 | $14K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 129 | $13K |
| 85730 | <1% | 4,674 | $13K | |
| 85610 | <1% | 5,705 | $13K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 501 | $11K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 227 | $10K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,987 | $9K |
| 85027 | <1% | 1,530 | $8K | |
| 84702 | <1% | 2,094 | $7K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $6K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 43 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 497 | $6K |
| 96376 | <1% | 621 | $6K | |
| 88304 | <1% | 266 | $5K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 70 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 184 | $5K |
| 93971 | <1% | 115 | $5K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 64 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 171 | $3K |
| 90715 | <1% | 176 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 28 | $3K |
| 88342 | <1% | 108 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,009 | $2K |
| 0004A | <1% | 58 | $2K | |
| 84484 | <1% | 5,108 | $2K | |
| 81001 | <1% | 4,278 | $2K | |
| 87652 | <1% | 139 | $2K | |
| 93970 | <1% | 12 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 12 | $2K |
| 83690 | <1% | 4,627 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 38 | $1K |
| 84703 | <1% | 4,562 | $1K | |
| 82962 | <1% | 2,070 | $1K | |
| 86703 | <1% | 164 | $1K | |
| 76641 | <1% | 26 | $1K | |
| 73630 | <1% | 292 | $1K | |
| 0003A | <1% | 26 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 64 | $1K |
| 76830 | Ultrasound, transvaginal | <1% | 131 | $990.74 |
| 73562 | <1% | 275 | $928.68 | |
| 81003 | <1% | 1,536 | $851.49 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 12 | $837.53 |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,757 | $803.25 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,084 | $716.43 |
| 73030 | <1% | 146 | $682.37 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 220 | $638.47 |
| 76642 | <1% | 12 | $611.75 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 569 | $518.06 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,189 | $503.80 |
| 81025 | <1% | 303 | $490.72 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 947 | $476.02 |
| 80051 | <1% | 33 | $453.33 | |
| 73610 | <1% | 139 | $324.23 | |
| 85378 | <1% | 1,056 | $306.66 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,099 | $300.71 |
| 82947 | <1% | 1,016 | $284.17 | |
| 0012A | <1% | 15 | $272.56 | |
| 83735 | <1% | 251 | $244.12 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 14 | $208.94 |
| 87040 | <1% | 405 | $110.84 | |
| 84450 | <1% | 281 | $109.87 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 219 | $105.68 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 121 | $78.18 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 659 | $68.95 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 330 | $64.85 |
| 84460 | <1% | 328 | $58.23 | |
| 84075 | <1% | 325 | $46.37 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 27 | $43.38 |
| 84155 | <1% | 324 | $43.04 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,821 | $42.04 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,517 | $40.43 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 313 | $39.47 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 78 | $38.28 |
| 86140 | <1% | 51 | $38.09 | |
| J3490 | Unclassified drugs | <1% | 46 | $34.03 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 714 | $29.28 |
| 82248 | <1% | 330 | $24.70 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,363 | $23.63 |
| 85651 | <1% | 38 | $23.04 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 662 | $9.17 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 42 | $8.37 |
| 82247 | <1% | 325 | $6.77 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,129 | $5.93 |
| 82040 | <1% | 326 | $4.14 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 153 | $0.86 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 30 | $0.74 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 16 | $0.15 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 14 | $0.01 |
| 99429 | 0% | 23 | $0.00 | |
| 83050 | 0% | 167 | $0.00 | |
| 86803 | 0% | 15 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 27 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 40 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 26 | $0.00 |
| 87070 | 0% | 72 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 16 | $0.00 |
| 83605 | 0% | 166 | $0.00 | |
| 82553 | 0% | 18 | $0.00 | |
| 91300 | 0% | 844 | $0.00 | |
| 82375 | 0% | 165 | $0.00 | |
| 73130 | 0% | 39 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBARRITT, KENNETH (SENIOR VICE PRESIDENT)
Parent organizationBETH ISRAEL MEDICAL CENTER
| Provider | Location | Paid |
|---|---|---|
| ST Lukes Roosevelt Hospital Center | New York, NY | $190.49M |
| Beth Israel Medical Center | New York, NY | $1.61M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.